CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

pERC Recommendation: Recommends with conditions

For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: March 20, 2015

This information is current as of January 27, 2016.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Dec 1, 2015	Chronic lymphocytic leukemia or small lymphocytic lymphoma with or without chromosome 17 p deletion, who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine-based regimen including short progression-free interval after previous treatment.
AB	Funded	Aug 6, 2015	Ibrutinib for patients with CLL/SLL who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine based regimen.
SK	Funded	Oct 1, 2015	For patients with CLL/SLL who have received at least one prior therapy, for which one line of therapy was a chemo-immunotherapy combination, and who have relapsed within 3 years since chemo-immunotherapy, or for patients who have relapsed greater than 3 years since chemo-immunotherapy and re-treatment with chemo-immunotherapy is not clinically appropriate. For the first line treatment of patients with deletion 17p CLL/SLL.
MB	Funded	Jan 18, 2016	For patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine-based regimen.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Jul 14, 2015	Funding criteria: For patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine-based regimen. Renewal criteria: Patient has experienced no disease progression while on Imbruvica therapy. Initial and renewal approval period: 1 year.
NS	Funded	Nov 2, 2015	As a treatment option for patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine-based regimen, including : • Patients who received prior fludarabine-based treatment and had a progression free interval of less than three years • Patients who received prior fludarabine-based treatment and had a progression free interval of greater than three years, but are now considered unfit for fludarabine-based retreatment due to age ≥ 70, or age ≥ 65 and the presence of comorbidities (Cumulative Illness Rating Scale [CIRS] ≥ 6 or creatinine clearance <70ml/min) • Patients who did not receive prior fludarabine-based treatment because they were considered unfit, and who relapsed after at least two cycles of alkylator-based therapy, regardless of the progression free interval after that therapy.
NB	Funded	Oct 14, 2015	For the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine-based regimen.
NL	Funded	Dec 1, 2015	For patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy and are considered inappropriate for treatment or re-treatment with a fludarabine-based regimen.
PEI	Under provincial consideration*		

* *Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product

that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.